Citations

Clear

410 citation(s) found for "Shu, Yu".

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling
Hage, Stephanie , Kinkade, Serena , Flemming, Kelly D. , Kim, Helen , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying, Thompson, Richard E. , Awad, Issam A. , Huston, John , Flemming, Kelly D , Kim, Helen , Torbey, Michel , Huang, Judy , Shu, Yunhong , Selwyn, Reed , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Girard, Romuald , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 31-39

10.1161/strokeaha.123.044083 | PMID 38134265 Get It

BACKGROUND: Quantitative susceptibility mapping (QSM) and dynamic contrast-enhanced quantitative perfusion (DCEQP) magnetic resonance imaging sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cerebral cavernous malformations. We assessed their prospective changes in a multisite trial-readiness project. METHODS: Patients with cavernous malformation and symptomatic hemorrhage (SH) in the prior year, without prior or planned lesion resection or irradiation were enrolled. Mean QSM and DCEQP of the SH lesion were acquired at baseline and at 1- and 2-year follow-ups. Sensitivity and specificity of biomarker changes were analyzed in relation to predefined criteria for recurrent SH or asymptomatic change. Sample size calculations for hypothesized therapeutic effects were conducted. RESULTS: We logged 143 QSM and 130 DCEQP paired annual assessments. Annual QSM change was greater in cases with SH than in cases without SH ( P =0.019). Annual QSM increase by ≥6% occurred in 7 of 7 cases (100%) with recurrent SH and in 7 of 10 cases (70%) with asymptomatic change during the same epoch and 3.82× more frequently than clinical events. DCEQP change had lower sensitivity for SH and asymptomatic change than QSM change and greater variance. A trial with the smallest sample size would detect a 30% difference in QSM annual change during 2 years of follow-up in 34 or 42 subjects (1 and 2 tailed, respectively); power, 0.8, α=0.05. CONCLUSIONS: Assessment of QSM change is feasible and sensitive to recurrent bleeding in cavernous malformations. Evaluation of an intervention on QSM percent change may be used as a time-averaged difference between 2 arms using a repeated measures analysis. DCEQP change is associated with lesser sensitivity and higher variability than QSM. These results are the basis of an application for certification by the US Food and Drug Administration of QSM as a biomarker of drug effect on bleeding in cavernous malformations. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03652181.
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome
Flemming, Kelly D. , Kim, Helen , Hage, Stephanie , Mandrekar, Jay , Kinkade, Serena , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying , Thompson, Richard E. , Awad, Issam A. , Huston, John , Torbey, Michel , Huang, Judy , Shu, Yunhong , Lanzino, Giuseppe , Selwyn, Reed , Hart, Blaine , Mabray, Marc C , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Flemming, Kelly D , Kim, Helen , Girard, Romuald , Lanzino, Giuseppe , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 22-30

10.1161/strokeaha.123.044068 | PMID 38134268 Get It

BACKGROUND: Cerebral cavernous malformation with symptomatic hemorrhage (SH) are targets for novel therapies. A multisite trial-readiness project ( https://www.clinicaltrials.gov ; Unique identifier: NCT03652181) aimed to identify clinical, imaging, and functional changes in these patients. METHODS: We enrolled adult cerebral cavernous malformation patients from 5 high-volume centers with SH within the prior year and no planned surgery. In addition to clinical and imaging review, we assessed baseline, 1- and 2-year National Institutes of Health Stroke Scale, modified Rankin Scale, European Quality of Life 5D-3 L, and patient-reported outcome-measurement information system, Version 2.0. SH and asymptomatic change rates were adjudicated. Changes in functional scores were assessed as a marker for hemorrhage. RESULTS: One hundred twenty-three, 102, and 69 patients completed baseline, 1- and 2-year clinical assessments, respectively. There were 21 SH during 178.3 patient years of follow-up (11.8% per patient year). At baseline, 62.6% and 95.1% of patients had a modified Rankin Scale score of 1 and National Institutes of Health Stroke Scale score of 0 to 4, respectively, which improved to 75.4% ( P =0.03) and 100% ( P =0.06) at 2 years. At baseline, 74.8% had at least one abnormal patient-reported outcome-measurement information system, Version 2.0 domain compared with 61.2% at 2 years ( P =0.004). The most common abnormal European Quality of Life 5D-3 L domains were pain (48.7%), anxiety (41.5%), and participation in usual activities (41.4%). Patients with prospective SH were more likely than those without SH to display functional decline in sleep, fatigue, and social function patient-reported outcome-measurement information system, Version 2.0 domains at 2 years. Other score changes did not differ significantly between groups at 2 years. The sensitivity of scores as an SH marker remained poor at the time interval assessed. CONCLUSIONS: We report SH rate, functional, and patient-reported outcomes in trial-eligible cerebral cavernous malformation with SH patients. Functional outcomes and patient-reported outcomes generally improved over 2 years. No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial.
Abstract 15220: The Thermal Characteristics to Phrenic and Esophageal Injuries During Ablation of QDOTMICRO (50w-Qmode and 90w/4sec-Qmode+) vs 50w-TactiCath SE vs 50w-Thermocool Smart Touch: Findings From an In-Vivo Porcine S
Otsuka, Naoto , Nagashima, Koichi , Kurokawa, Sayaka , Hirata, Moyuru , Sawada, Masanaru , Nakai, Toshiko , Okumura, Yasuo , Watanabe, Ryuta , Wakamatsu, Yuji , Hirata, Shu

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15220 Get It

Introduction: Recently, there have been numerous strategies for treating atrial fibrillation, including the choice of catheters However, the thermal characteristics of each catheter, particularly in terms of safety, have not been fully understood. Hypothesis: Our aim was to characterize the thermal damage to collateral tissues during 50W-HPSD ablation and 90W/4sec-vHPSD ablation using three different ablation catheters. Methods: In 28 pigs, we implanted thermocouples on the superior vena cava, close to the phrenic nerve, and on the esophageal, close to the inferior vena cava. We performed endocardial ablation near the fiducial markers of the thermocouples using three different RF catheters: ablation index (AI)-guided HPSD (Qmode) and vHPSD ablation (Qmode+) with QDOTMICRO, lesion size index-guided HPSD ablation (targeting 5.0) with TactiCath Sensor Enabled (Tacti), and AI-guided HPSD ablation (targeting 400) with Thermocool Smart Touch (STSF). We measured tissue temperatures during ablation, including maximum tissue temperature (Tmax), time to maximum tissue temperature (t-Tmax), time to achieve a lethal temperature of 50°C (t-50°C), and time to return to baseline from Tmax (t-Tbase). Results: In terms of the frequency of esophageal injury, there were no significant differences among the different catheters. However, the depth of esophageal injury from the adventitia showed a significant difference. In terms of phrenic nerve injury, Tacti had the highest frequency compared to the other catheters (100%, p=0.0012). Tmax, t-Tmax, t-50°C, and t-Tbase showed significant differences, as shown in figure. Conclusions: The thermal effects on collateral tissues differ among the three different catheters and settings. STSF and Qmode result in a gradual increase in tissue temperature, while Tacti and Qmode+ lead to a rapid temperature increase. These distinct thermal distributions may contribute to the risk of phrenic nerve and esophageal injuries.
International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts
Timmins, Iain R. , Jones, Michael E. , O’Brien, Katie M. , Adami, Hans‐Olov , Aune, Dagfinn , Brantley, Kristen D. , Chen, Yu , DeHart, Jessica Clague , Clendenen, Tess V. , Fournier, A. , Hankinson, Susan E. , Houlston, Richard S. , Kirsh, Victoria A. , Linet, Martha S. , May, Anne M. , Rohan, Thomas E. , Ruddy, Kathryn J. , Sund, Malin , Vachon, Celine M. , Vatten, Lars J. , Visvanathan, Kala , Yuan, Jian‐Min , Zheng, Wei , Nichols, Hazel B. , Baglietto, Laura , Bertrand, Kimberly A , Brantley, Kristen D , Clague DeHart, Jessica , Clendenen, Tess V , Dossus, Laure , Eliassen, A Heather , Fletcher, Olivia , Fournier, Agnès , Håkansson, Niclas , Houlston, Richard S , Joshu, Corinne E , Kirsh, Victoria A , Kitahara, Cari M , Linet, Martha S , Park, Hannah Lui , Lynch, Brigid M , May, Anne M , Mellemkjær, Lene , Milne, Roger L , Palmer, Julie R , Ruddy, Kathryn J , Sánchez, Maria-Jose , Shu, Xiao-Ou , Steindorf, Karen , Sund, Malin , Vachon, Celine M. , Vatten, Lars J , Visvanathan, Kala , Weiderpass, Elisabete , Willett, Walter C , Wolk, Alicja , Zheng, Wei , Nichols, Hazel B , Sandler, Dale P , Jones, Michael E , O'Brien, Katie M , Aune, Dagfinn , Chen, Yu , Baglietto, Laura , Bertrand, Kimberly A. , Eliassen, A. Heather , Fletcher, Olivia , Håkansson, Niclas , Hankinson, Susan E. , Kitahara, Cari M. , Koh, Woon‐Puay , Milne, Roger L. , Palmer, Julie R. , Ricceri, Fulvio , Sánchez, María‐José , Shu, Xiao‐Ou , Smith-Byrne, Karl , Weiderpass, Elisabete , Willett, Walter C. , Wolk, Alicja , Sandler, Dale P. , Swerdlow, Anthony J. , Schoemaker, Minouk J.

Mayo Clinic

Journal of Clinical Oncology | December 11, 2023 | Volume: 42 | Issue: 8 | Pages: 927-939

10.1200/jco.23.01101 | PMID 38079601 Get It

PURPOSE There is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this study was to examine the association of physical activity with the risk of developing premenopausal breast cancer. METHODS We pooled individual-level data on self-reported leisure-time physical activity across 19 cohort studies comprising 547,601 premenopausal women, with 10,231 incident cases of breast cancer. Multivariable Cox regression was used to estimate hazard ratios (HRs) and 95% CIs for associations of leisure-time physical activity with breast cancer incidence. HRs for high versus low levels of activity were based on a comparison of risk at the 90th versus 10th percentiles of activity. We assessed the linearity of the relationship and examined subtype-specific associations and effect modification across strata of breast cancer risk factors, including adiposity. RESULTS Over a median 11.5 years of follow-up (IQR, 8.0-16.1 years), high versus low levels of leisure-time physical activity were associated with a 6% (HR, 0.94 [95% CI, 0.89 to 0.99]) and a 10% (HR, 0.90 [95% CI, 0.85 to 0.95]) reduction in breast cancer risk, before and after adjustment for BMI, respectively. Tests of nonlinearity suggested an approximately linear relationship ( Pnonlinearity = .94). The inverse association was particularly strong for human epidermal growth factor receptor 2–enriched breast cancer (HR, 0.57 [95% CI, 0.39 to 0.84]; Phet = .07). Associations did not vary significantly across strata of breast cancer risk factors, including subgroups of adiposity. CONCLUSION This large, pooled analysis of cohort studies adds to evidence that engagement in higher levels of leisure-time physical activity may lead to reduced premenopausal breast cancer risk.
Proposed Diagnostic Criteria for Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (P2.238)
Yoshida, Kunihiro , Kawarai, Toshitaka , Tada, Masayoshi, Nozaki, Hiroaki , Ikeda, Shu‐ichi , Nishizawa, Masatoyo , Konno, Takuya , Mizuno, Toshiki , Onodera, Osamu , Wszołek, Zbigniew K. , Ikeuchi, Takeshi

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p2.238 Get It

Frequency and Phenotype of Coexisting AQP4-IgG with Synaptic Autoantibodies in Patients Undergoing Serological Testing for CNS Inflammatory Disease (622)
Chen, John , Ζεκερίδου, Αναστασία , Ahsen, Nusrat, Fernández, Karen S. , Fulchiero, Rosanna , Mitchell, Wendy G. , Sieloff, Kurt, Shu, Huidy, Weinshenker, Brian, Kunchok, Amy , Flanagan, Eoin P. , Dubey, Divyanshu , Klein, Christopher J. , Lachance, Daniel Honore , Waubant, Emmanuelle L. , McKeon, Andrew , Pittock, Sean J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.622 Get It

MRI Reveals Connectivity of Cortical Lesions to White Matter Lesions in Multiple Sclerosis. (P6.107)
Tillema, Jan‐Mendelt , Weigand, Stephen D. , Mandrekar, Jayawant, Shu, Yunhong , Lucchinetti, Claudia F. , Pirko, Istvan, Port, John D.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p6.107 Get It

Deep phenotyping using cranial autonomic symptoms in migraine and cluster headache (P1-1.Virtual)
Chen, Shu‐Ting , Wu, Jr‐Wei , Chiang, Chia‐Chun

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.589 Get It

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
Innocenti, Federico , Mu, Wancen , Qu, Xueping , Ou, Fang‐Shu , Kabbarah, Omar , Blanke, Charles D. , Venook, Alan P. , Lenz, Heinz‐Josef , Rashid, Naim U. , Venook, Alan P , Ou, Fang-Shu

Mayo Clinic

Journal of Clinical Oncology | November 22, 2023 | Volume: 42 | Issue: 4 | Pages: 399-409

10.1200/jco.23.00825 | PMID 37992266 Get It

PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab with chemotherapy. We aimed to discover novel mutated genes associated with prognosis and differential response to therapy with the biologics. METHODS Primary tumor DNA from 548 patients was sequenced using FoundationOne. The effect of mutated genes and mutations on overall survival (OS) was tested adjusting for microsatellite instability status, BRAF V600E, all RAS mutations, arm, sex, and age. RESULTS The median number (lower-upper quartile) of mutated genes was 5 (3-7), 5 (3-6) in microsatellite stable and 12.5 (4.5-32) in microsatellite instability-high tumors. Mutated KRAS and APC were more frequent in Black (53% and 85%) than White (27% and 65%, respectively) patients while BRAF V600E was less frequent in Black (5%) than White (14%) patients. The median OS in patients with BRAF non-V600E (2.2% of patients) was 31.9 months (95% CI, 15.1 to not applicable [NA]) similar to that of BRAF wild-type (WT) patients (31.2 months [95% CI, 29.0 to 33.9]). Mutated LRP1B (10.7% of patients) was associated with improved OS compared with WT LRP1B (hazard ratio, 0.57 [95% CI, 0.40 to 0.80]). RNF43 (5.6% of patients) interacted with treatment arms as, in the cetuximab arm, patients with mutated RNF43 had a median OS of 11.5 (95% CI, 10.8 to NA) months compared with 30.1 (95% CI, 24.9 to 35.3) months in patients with WT RNF43, whereas in the bevacizumab arm, patients with mutated RNF43 had a median OS of 25.0 (95% CI, 14.2 to NA) months compared with 31.3 (95% CI, 29.0 to 34.3) months in patients with WT RNF43. CONCLUSION These results can provide new tools to predict patient outcome and improve therapeutic decisions and trial participation in patient minorities. The molecular alterations identified in this study may direct biomarker-driven studies.